[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"critically-ill\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:critically-ill":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,17,0,[8,48,71,99,129,156,184,212,237,262,287,315,336,358,384,422,451],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":32,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100612143","factor-associated-with-mortality-in-the-icu-100612143",false,"NCT07249749","Factor Associated With Mortality in the ICU","Factors Associated With Mortality in the Intensive Care Unit From the Orinoco Region. An Observational Trial","ICUMortal","Inclusion Criteria:\n\n* All adult patients older than 18 admitted to the intensive care unit during the study period.\n\nExclusion Criteria:\n\n* Patients admitted for intermediate care (low therapeutic intervention with a TISS \\[Therapeutic Intervention Scoring System\\] - 28 score below 20 points). Patients derived to other institutions.","ALL","18 Years","100 Years",{"count":21,"type":22},1000,"ESTIMATED","OBSERVATIONAL","ICU mortality indicates the severity of disease, healthcare quality, and the efficacy of interventions. The severity scores are tools to predict the risk of mortality in the ICU, and the APACHE II score is frequently used for this purpose. However, studies validating the score in Colombia are limited. There is uncertainty about the precision and discrimination capacity of the APACHE II score in a population that varies from the original, with varying diseases, and in a different timeline. The investigators determined to evaluate: 1. Evaluate the rate of mortality in the ICU by type of disease and type of admission. 2. The factors associated with mortality. 3. Validate the performance of the APACHE II score as a predictor of mortality.",[26,27,28,29,30,31],"Critically Ill","Intensive Care (ICU)","Intensive Care Medicine","Mortality","Mortality Prediction","Mortality in Intensive Care Units",[26,33,29,34],"Intensive Care Unit","Colombia","RECRUITING","2026-05-25",{"date":38,"type":39},"2026-05-27","ACTUAL",{"date":41,"type":39},"2026-01-10",{"date":43,"type":22},"2028-12-21",{"name":45,"class":46},"Hospital Departamental de Villavicencio","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":56,"targetDuration":58,"studyType":23,"phases":4,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":47},"100401074","heterogeneity-of-critical-illness-a-cohort-study-100401074","NCT04502511","Heterogeneity of Critical Illness: a Cohort Study","Heterogeneity of Critical Illness: Exploring New Risk Factors for Severity of Disease in Intensive Care Patients. A Cohort Study","HEALICS","Inclusion Criteria:\n\n* Adults Definition: age ≥18 years.\n* Emergency admission to the ICU Definition: patients who are acutely admitted to the ICU due to acute or unexpected critical illness, either from the emergency department or the ward or transferred from an ICU (or a ward) from another hospital.\n\nExclusion Criteria:\n\n* Planned admission\n* Absence of an invasive arterial or venous line for blood sampling.\n* Any continued cardiopulmonary resuscitation efforts upon admission which limit access to the patient for research activities.\n* Main ICU admission reason chronic (non-invasive) home ventilation\n* Main ICU admission reason normothermic treatment after cardiac arrest\n* Main ICU admission reason ischemic stroke, intracerebral bleeding, or isolated neurotrauma\n* Main ICU admission reason Coronavirus Disease 2019 (COVID-19)\n* Solid organ or hematopoietic stem cell transplant during current hospital admission\n* Strict isolation due to any contagious disease\n* No informed consent",{"count":57,"type":22},5000,"1 Year","Rationale: There is large heterogeneity in disease states of critically ill patients at ICU admittance and there is also large heterogeneity in their disease severity during ICU stay. Still, some patients may show remarkable similarities in disease patterns. There is a lack of understanding of causal mechanisms that lead to divergent outcomes in critically ill patients, and at the same time different diseases may share common underlying, yet unidentified, causal pathways that could explain similarities between different diseases.\n\nObjective: To explore the association between patient characteristics and the severity of organ failure in critically ill patients admitted to the ICU Study design: Prospective cohort study Study population: Adult critically ill patients in the ICU Intervention (if applicable): not applicable Main study parameters\u002Fendpoints: Maximum severity of organ failure observed during ICU stay measured by the maximum SOFA score and quality of life at one year follow-up",[26,61],"Organ Failure, Multiple","2026-05-21",{"date":64,"type":39},"2026-05-26",{"date":66,"type":39},"2022-01-01",{"date":68,"type":22},"2030-01-01",{"name":70,"class":46},"University Medical Center Groningen",{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":80,"conditions":81,"keywords":87,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":47},"100610009","induction-agent-choice-with-early-mortality-and-prognostic-outcomes-in-critically-ill-patients-100610009","NCT07222007","Induction Agent Choice With Early Mortality and Prognostic Outcomes in Critically Ill Patients","Association of Induction Agent Choice With Early Mortality and Prognostic Outcomes in Critically Ill Patients: A Large-Scale Retrospective Cohort Analysis","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Admission to the surgical ICU for critical care\n* Administration of one of the studied induction agents\n* Availability of complete clinical data\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Absence of documented induction agent administration\n* Incomplete or missing medical records",{"count":79,"type":22},4,"The aim of this retrospective cohort study is to compare the safety and efficacy of induction agents for tracheal intubation in critically ill adult patients.",[26,82,83,84,85,86],"Intubation Complication","Oxygenation","Airway Management","Propofol","Ketamine",[88],"intubation, critically ill patients, airway management","2026-04-11",{"date":91,"type":39},"2026-04-14",{"date":93,"type":22},"2026-04-18",{"date":95,"type":22},"2026-07-01",{"name":97,"class":98},"Zeliha Alicikus","OTHER_GOV",{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":109,"phases":110,"briefSummary":112,"conditions":113,"keywords":114,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":47},"100470723","feasibility-of-end-tidal-oxygen-concentration-monitoring-during-preoxygenation-for-intubation-in-the-intensive-care-unit-100470723","NCT05409573","Feasibility of End-tidal Oxygen Concentration Monitoring During Preoxygenation for Intubation in the Intensive Care Unit.","Feasibility of End-tidal Oxygen Concentration Monitoring During Preoxygenation for Intubation in the Intensive Care Unit. First Part, Preliminary Study of the IMPROVE Global Project","IMPROVE-Pre","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Requiring an intubation in ICU for acute respiratory failure defined as a respiratory rate ≥ 25\u002Fmin or clinical signs of respiratory distress or hypoxemia defined as oxygen requirement ≥ 15L\u002Fmin or FiO2 ≥80% to maintain SpO2 ≥92% or a PaO2\u002FFiO2 ratio \\\u003C100 mmHg\n* With preoxygenation by noninvasive ventilation\n\nExclusion Criteria:\n\n* Intubation for cardiac arrest\n* EtO2 monitoring not available\n* Pulsed oxygen saturation monitoring specific for the study not available\n* Preoxygenation by high-flow nasal oxygen therapy or bag-mask ventilation\n* Allergy to lidocaine (for local nasal anesthesia)\n* Previously\n* Patient not affiliated or excluded from social protection, or under law protection (namely minors, pregnant or breastfeeding women, persons deprived of their liberty by court or administrative decision)\n* Previously included in the study",{"count":108,"type":22},30,"INTERVENTIONAL",[111],"NA","Intubation is a common procedure in the intensive care unit. Hypoxemia is the most frequent complication of this procedure.\n\nMonitoring the end-tidal of oxygen is recommended in operating room (OR). End-tidal of oxygen (EtO2) \\>90% is an indication of a correct preoxygenation.\n\nThis monitoring is not used in routine in intensive care unit (ICU). There is no recommendation on the monitoring of end-tidal of oxygen in intensive care unit. In practice, clinicians use pulsed oxygen saturation (SpO2) to determine whether the patient is sufficiently preoxygenated. However, this parameter is not a good indicator of a correct preoxygenation.\n\nIn the OR, patients are compliant during the preoxygenation period and the measure of EtO2 with the face mask monitor is considered reliable because i) mask leakage is minimal and ii) the patient can breathe slowly and regularly.\n\nTheses conditions are not available in critical ill patients requiring emergency intubation. EtO2 measured on the facemask may not reflect true EtO2.\n\nThis concern about the reliability of EtO2 measurement via the facemask justifies that we conduct a study to compare EtO2 measured on a facemask (facemask EtO2) to EtO2 measured in pharynx (via e nasopharyngeal catheter).\n\nThe aim of this study is to determine whether the measurement of EtO2 on facemask is reliable in patients in ICU.",[26],[115,116,117,118,119],"Preoxygenation","intubation","end-tidal of oxygen","intensive care unit","critically ill patients","2026-01-28",{"date":122,"type":39},"2026-01-29",{"date":124,"type":39},"2022-12-23",{"date":126,"type":22},"2027-12",{"name":128,"class":46},"Centre Hospitalier Régional d'Orléans",{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":135,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":137,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":138,"conditions":139,"keywords":141,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":47},"100538002","analgesia-nociception-index-to-explore-autonomic-nervous-system-in-patients-with-continuous-renal-replacement-therapy-100538002","NCT06285162","Analgesia Nociception Index to Explore Autonomic Nervous System in Patients With Continuous Renal Replacement Therapy","Analgesia Nociception Index and Autonomic Nervous System Exploration During Continuous Renal Replacement Therapy in Intensive Care Patients.","UFANI","Inclusion Criteria:\n\n* Continuous renal replacement therapy in intensive care unit\n* Initiation of net ultrafiltration according to the protocol of the department or to EARLYDRY study (NCT 05817539) (3 criteria required):\n\n  * Fluid overload \\> 5% or peripheral oedema\n  * Noradrenaline equivalent \\\u003C0.5μg\u002Fkg\u002Fmin\n  * No peripheral hypoperfusion\n* Invasive blood pressure monitoring\n* Central venous line in superior vena cava territory\n* Regular sinus rhythm\n* Patient awake or Richmond Agitation and Sedation Scale \\> -3\n\nExclusion Criteria:\n\n* Ongoing administration of inotropes\n* Ongoing administration of beta blockers\n* Current administration of alpha-2 agonists\n* History of dysautonomia\n* Pregnant or breast-feeding woman\n* Mechanical circulatory assistance\n* Opposition to participate\n* Adults under legal protection\n* Persons deprived of their liberty by judicial or administrative decision",{"count":108,"type":22},"The Analgesia Nociception Index (ANI) reflects the balance between sympathetic and parasympathetic tone. It is based on a specific interpretation of the R-R interval variation. During fluid removal by net ultrafiltration in patients with fluid overload and continuous renal replacement therapy, some data suggest that haemodynamic variation could be induced by the autonomic nervous system. The study aims to investigate ANI variations in this context and their association with the haemodynamic variations observed.",[26,140],"Renal Replacement Therapy",[142,143,144,145,146],"Analgesia Nociception Index","R-R interval","autonomic nervous system","haemodynamic","fluid removal","2026-01-14",{"date":149,"type":39},"2026-01-15",{"date":151,"type":39},"2026-01-09",{"date":153,"type":22},"2027-04",{"name":155,"class":46},"Hospices Civils de Lyon",{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":4,"eligibilityCriteria":162,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":163,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":165,"conditions":166,"keywords":170,"overallStatus":175,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":4},"100618985","fluid-balance-in-acute-kidney-injury-in-critically-ill-patients-100618985","NCT07338734","Fluid Balance in Acute Kidney Injury in Critically Ill Patients","Fluid Balance During Early Hours of Acute Kidney Injury in Critically Ill Patients","Inclusion Criteria:\n\n* Adults aged 18 years or older admitted to the ICU.\n* Patients with no AKI at ICU admission.\n* AKI secondary to (prerenal cause-renal and post renal with manifestation of hypovolemia)-postoperative settings-On top of CKD up to Stage 111b-Compansated heart failure with indication of fluid therapy\n\nExclusion Criteria:\n\n* Patients with pre-existing end-stage renal disease requiring dialysis.\n* Patients with known chronic kidney disease stage 4 or higher.\n* ICU readmissions during the same hospitalization.\n* Patients who received renal replacement therapy before ICU admission\n* Patients with AKI with manifestation of over load as pulmonary edema- pulmonary embolism-Acute decompensated heart failure",{"count":164,"type":22},120,"This prospective observational cohort study evaluates if fluid balance in the first 48 hours of ICU admission is linked to acute kidney injury (AKI) in critically ill adults. Patients without AKI at entry will have fluids tracked hourly via charts, weights, and labs to assess AKI risk by KDIGO criteria within 7 days. Findings may guide better fluid management to lower AKI rates.",[167,168,169,26],"Fluid Balance","Acute Kidney Injury","Critically Ill Acute Kidney Injury",[167,171,172,173,174],"acute kidney injury","AKI","critically ill","KDIGO criteria","NOT_YET_RECRUITING","2026-01-04",{"date":147,"type":39},{"date":179,"type":22},"2026-01",{"date":181,"type":22},"2027-02",{"name":183,"class":46},"Assiut University",{"id":185,"slug":186,"hasResults":11,"nctId":187,"briefTitle":188,"officialTitle":188,"acronym":4,"eligibilityCriteria":189,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":190,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":192,"conditions":193,"keywords":195,"overallStatus":175,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":205,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":4},"100618352","transducer-levelling-errors-in-everyday-icu-practice---a-multicentre-blinded-observational-study-100618352","NCT07330505","Transducer Levelling Errors in Everyday ICU Practice - A Multicentre Blinded Observational Study","Inclusion Criteria:\n\n* Age ≥18 years\n* ICU admission\n* Mechanically ventilated\n* Arterial catheter for MAP\n* Central venous catheter for CVP\n* Ongoing vasopressor therapy\n\nExclusion Criteria:\n\n* Severe hemodynamic or respiratory instability\n* Contraindications for lateral positioning\n* Expected survival \\\u003C24 hours",{"count":191,"type":22},60,"Invasive pressure monitoring (arterial blood pressure via arterial catheter and central venous pressure via central venous catheter) is fundamental to clinical decision-making in intensive care. Treatment with vasopressors, fluids, and nursing interventions depends on accurate measurements. Because pressure transducers are hydrostatic, even small levelling errors can produce clinically relevant deviations (approximately 1 mmHg per 1.3 cm of vertical misplacement). Such errors may contribute to inappropriate therapy, for example under-recognition of hypotension, unnecessary vasopressor escalation, or missed venous congestion.\n\nThis prospective, multicenter, blinded observational study will quantify transducer levelling deviations during routine ICU care and evaluate whether clinically relevant deviations are associated with treatment decisions. Adult mechanically ventilated ICU patients with an arterial catheter, a central venous catheter, and ongoing vasopressor therapy will be included at hospitals in Västra Götalandsregionen, Sweden. Two blinded reference lines\u002Fsensors will be placed at predefined physiological zero levels for MAP and CVP and connected in parallel to the patient monitoring system. Continuous deviation (mmHg) between the clinical transducer position and the blinded reference level will be recorded for 8 hours while clinical staff remain unaware of the reference setup. MAP\u002FCVP-related treatment decisions (e.g., vasopressor adjustments, fluid therapy, and nursing interventions) will be recorded with timestamps.\n\nThe study will provide real-world data on the magnitude and frequency of invasive pressure transducer misalignment in daily ICU practice and its potential relationship to patient management.",[26,194],"Haemodynamic Instability",[196,197,198,199,200,201,202,203,204],"Invasive arterial blood pressure monitoring","Central venous pressure monitoring","Pressure transducer leveling","Pressure transducer positioning","Intensive care unit","Critically ill","Patient safety","Mean arterial pressure","Right atrial pressure",{"date":151,"type":39},{"date":207,"type":22},"2026-02-01",{"date":209,"type":22},"2027-02-01",{"name":211,"class":98},"Vastra Gotaland Region",{"id":213,"slug":214,"hasResults":11,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":218,"eligibilityCriteria":219,"healthyVolunteers":11,"sex":17,"minAge":220,"maxAge":221,"enrollmentInfo":222,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":224,"conditions":225,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":47},"100443547","opportunistic-pkpd-trial-in-critically-ill-children-optic-100443547","NCT05055830","Opportunistic PK\u002FPD Trial in Critically Ill Children (OPTIC)","Clinically Integrated Opportunistic PK\u002FPD Trial in Critically Ill Children","OPTIC","Inclusion Criteria:\n\nTo be eligible for enrollment, a potential participant must meet all the following criteria:\n\n1. Participant is \\\u003C21 years old on admission\n2. Participant is admitted to the Pediatric Cardiac Intensive Care Unit\n3. Parent\u002Flegal guardian\u002Fadult participant can understand the consent process and is willing to provide informed consent\u002Fassent\n4. Participant is receiving one or more of the study drugs of interest at the time of enrollment\n\nExclusion Criteria:\n\n1\\. Any condition which would make the participant, in the opinion of the investigator, unsuitable for the study","0 Months","20 Years",{"count":223,"type":22},2000,"OPTIC is a prospective, open-label, non-randomized study of multiple medications administered to approximately 2000 children in the pediatric cardiac intensive care unit (PCICU) per routine clinical car by their treating provider. The purpose of this study is to characterize the PK of drugs routinely administered to children per standard of care using opportunistic and scavenged samples. The prescribing of drugs to children will not be part of this protocol.\n\nAfter the child\u002Fadult (\\\u003C21 years of age) is consented\u002Fenrolled, demographic and clinical data will be extracted from the EHR. Biospecimen information (including date and time of sample collection) will be collected.\n\nData analysis will be conducted on all participants with at least 2 evaluable samples. The protocol represents minimal risk to the children\u002Fadults who provide body fluid for this study, including potential loss of confidentiality (samples will be assigned a unique accession number) and risks associated with blood draws. Adverse Events (AEs)\u002FSerious Adverse Events (SAEs) caused by the study specimen collections will be monitored and recorded in the Electronic Data Capture (EDC) system.",[226,26,227],"Cardiac Disease","Children, Adult","2025-11-13",{"date":230,"type":39},"2025-11-14",{"date":232,"type":39},"2021-10-05",{"date":234,"type":22},"2028-10-30",{"name":236,"class":46},"Duke University",{"id":238,"slug":239,"hasResults":11,"nctId":240,"briefTitle":241,"officialTitle":242,"acronym":4,"eligibilityCriteria":243,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":244,"enrollmentInfo":245,"targetDuration":4,"studyType":109,"phases":247,"briefSummary":248,"conditions":249,"keywords":250,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":257,"completionDateStruct":258,"leadSponsor":260,"locationsCount":47},"100603990","parasternal-intercostal-muscle-thickening-as-an-additive-weaning-criterion-100603990","NCT07143695","Parasternal Intercostal Muscle Thickening as an Additive Weaning Criterion","Parasternal Intercostal Muscle Thickening as an Additive Weaning Criterion to Minimize Re-intubation Rate: a Randomized Controlled Trial","Inclusion Criteria:\n\n* critically ill patient mechanically ventilated for 24 hours or more first spontaneous breathing trial\n\nExclusion Criteria:\n\n* patient refusal difficult ultrasound views tracheostomized patient neuromuscular disorders","65 Years",{"count":246,"type":22},200,[111],"Increased days of MV are not without hazards, including barotraumas and ventilator-associated pneumonia. Similarly, premature separation of MV is associated with increased mortality secondary to adverse cardiorespiratory events. Therefore, the time of weaning should be wisely evaluated. There is growing evidence concerning respiratory muscles dysfunction that contributes to difficulty or prolonged liberation from MV.",[26],[251,252,253],"Weaning","re-intubation","mechanical ventilation","2025-09-01",{"date":256,"type":39},"2025-09-08",{"date":254,"type":39},{"date":259,"type":22},"2026-08-31",{"name":261,"class":46},"Cairo University",{"id":263,"slug":264,"hasResults":11,"nctId":265,"briefTitle":266,"officialTitle":266,"acronym":267,"eligibilityCriteria":268,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":269,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":271,"conditions":272,"keywords":275,"overallStatus":175,"whyStopped":4,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":279,"startDateStruct":281,"completionDateStruct":283,"leadSponsor":284,"locationsCount":286},"100434270","mini-fluid-challenge-assessment-a-comparison-among-three-hemodynamic-tools-100434270","NCT04934943","\"Mini Fluid Challenge Assessment: a Comparison Among Three Hemodynamic Tools\"","MINI3","Inclusion criteria\n\n1\\) Acute circulatory failure defined as:\n\n* SAP ≤ 90 mmHg (or a decrease \\> 50 mm Hg in hypertensive patients)\n* or a mean arterial pressure (MAP) ≤ 70 mmHg\n* or the use of vasopressors to maintain SAP \\>90 mmHg,\n* associated with skin mottling; tachycardia ≥100 beats\u002Fmin; urinary flow ≤0.5 mL\u002Fkg for at least 2 hours; blood lactate level ≥4 mmol\u002FL.\n\nExclusion criteria:\n\n* known severe myocardial or valvular dysfunction\n* cardiac arrhythmias\n* severe acute respiratory distress syndrome\n* on-going haemodialysis or continuous hemofiltration\n* moribund patients\n* persistent low quality of the arterial signal affecting hemodynamic monitoring measurements\n* poor echographic windows.",{"count":270,"type":22},45,"The mini fluid challenge (mini\\_FC) is a functional hemodynamic test which has been used in different clinical contexts to assess fluid responsiveness.\n\nThis test is performed by rapidly injecting a small aliquot of fluid (100 ml over 1 minute), which is followed by the infusion of the residual aliquot of fluid.\n\nSince the threshold of the mini\\_FC identified by the literature is rather small (5% of stroke volume (SV) increase after the 100 ml bolus to discriminate between responder and non-responder), it is crucial that the hemodynamic tool assessing this change could be reliable. Moreover, the SV changes with inspiratory\u002Fexpiratory movements and the increase after the mini\\_FC should also consider the physiological fluctuations of the SV.\n\nIn the literature this test has been performed by means of tolls with different least significant change of the SV. The least significant change (LSC) represents the smallest difference between successive measurements of SV that can be considered to be a real change and not attributable to chance.\n\nThe purpose of this study is to assess the agreement among MOSTCARE system (4.5\\& of SV LSC described in the literature) and the echocardiography (about 10% of SV LSC described in the literature) with the PICCO system (about 1% of SV LSC described in the literature - considered the gold standard) in discriminating fluid responsiveness after a mini\\_FC",[273,274,26],"Sepsis","Shock, Septic",[276,277],"Fluid challenge","Functional hemodynamic test","2025-06-25",{"date":280,"type":39},"2025-06-29",{"date":282,"type":22},"2025-08-01",{"date":282,"type":22},{"name":285,"class":46},"Humanitas Clinical and Research Center",2,{"id":288,"slug":289,"hasResults":11,"nctId":290,"briefTitle":291,"officialTitle":292,"acronym":4,"eligibilityCriteria":293,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":294,"targetDuration":4,"studyType":109,"phases":295,"briefSummary":296,"conditions":297,"keywords":301,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":305,"lastUpdatePostDateStruct":306,"startDateStruct":308,"completionDateStruct":310,"leadSponsor":312,"locationsCount":314},"100552496","efficacy-of-sglt2-inhibitors-in-adults-with-sepsis-100552496","NCT06473844","Efficacy of SGLT2 Inhibitors in Adults With Sepsis","Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitors in Adults With Sepsis: A Feasibility Study for a Multicenter Double-Blind Randomized Placebo-Controlled Trial","Inclusion Criteria:\n\n* Aged 18 years or above\n* New onset of sepsis within 48 hours defined according to the Sepsis-3 criteria. (≥2 SOFA)\n* Provision of signed and dated informed consent form from participant or surrogate\n* Ability to take and adhere to oral and enteral medication regimen\n* Willingness to comply\n\nExclusion Criteria:\n\n* Current or recent use of SGLT2 inhibitors (within 12wks prior to randomization)\n* Impaired renal function\n* Clinically unstable or in refractory hypotension\n* History of ketoacidosis\n* Gastrointestinal surgery or GI absorption \u002F malabsorption disorder\n* Pregnancy\n* Known allergic or hypersensitivity reactions to any SGLT2 inhibitors\n* Treatment with another investigational drug or other interventions within 30 days prior to trial",{"count":191,"type":22},[111],"Goal of this clinical trial is to examine the safety and efficacy of SGLT2 inhibitors on the clinical outcomes in patients with sepsis. Main study outcomes are as follows:\n\n(i) Primary objective is to examine the efficacy and safety of SGLT2 inhibitors on clinical outcomes in patients with sepsis.\n\n(ii) Secondary objective is to examine the effect of SGLT2 inhibitors on inflammatory markers in patients with sepsis.",[273,298,299,26,300],"Inflammation","SGLT2 Inhibitors","Organ Dysfunction Syndrome",[302,273,303,26,304],"SGLT2 inhibitors","Inflammatory Markers","Organ dysfunction","2025-03-17",{"date":307,"type":39},"2025-03-19",{"date":309,"type":39},"2025-03-05",{"date":311,"type":22},"2027-02-28",{"name":313,"class":98},"Hospital Authority, Hong Kong",3,{"id":316,"slug":317,"hasResults":11,"nctId":318,"briefTitle":319,"officialTitle":320,"acronym":321,"eligibilityCriteria":322,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":323,"targetDuration":4,"studyType":109,"phases":325,"briefSummary":326,"conditions":327,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":328,"lastUpdatePostDateStruct":329,"startDateStruct":331,"completionDateStruct":333,"leadSponsor":334,"locationsCount":47},"100503085","remote-ischemic-preconditioning-in-septic-patients-100503085","NCT05830669","Remote Ischemic Preconditioning in Septic Patients","Effect of Remote Ischemic Preconditioning in Septic Patients on Cell Cycle Arrest Biomarkers - the RIPC-ICU Randomized Clinical Trial","RIPC-ICU","Inclusion Criteria:\n\n* Adult patients (age ≥18 years)\n* Critically ill patients with sepsis \\\u003C 12 hours\n* Invasive ventilation for at least 24 hours (propofol-free-sedation) and\u002For vasopressor therapy\n* Unrestricted intensive care for at least 72 hours\n* Written informed consent\n\nExclusion Criteria:\n\n* Pre-existing AKI\n* (Glomerulo-)nephritis, interstitial nephritis, vasculitis\n* Chronic kidney disease with estimated glomerular filtration rate (eGFR) \\\u003C 30 ml\u002Fmin\u002F1.73m²\n* Chronic dialysis dependency\n* Kidney transplant in the last 12 months\n* Oral antidiabetics, sulfonamides or nicorandil\n* Pregnancy or breastfeeding\n* Do-not-reanimate order\n* Participation in another interventional trial involving kidney outcomes within the last 3 months\n* Dependency on the investigator or center",{"count":324,"type":22},64,[111],"Acute kidney injury is a well-recognized complication in critically ill patients. Up to date there is no clinically established method to reduce the incidence or the severity of acute kidney injury.\n\nRemote ischemic preconditioning (RIPC) will be induced by three cycles of upper limb ischemia.\n\nThe aim of the study is to reduce the incidence of AKI by implementing remote ischemic preconditioning (identified by the urinary biomarkers tissue inhibitor of metalloproteinases-2 (TIMP-2) and insulin-like growth factor-binding protein 7(IGFBP7)",[26,168,273],"2024-12-06",{"date":330,"type":39},"2024-12-12",{"date":332,"type":39},"2023-05-11",{"date":179,"type":22},{"name":335,"class":46},"Universität Münster",{"id":337,"slug":338,"hasResults":11,"nctId":339,"briefTitle":340,"officialTitle":341,"acronym":342,"eligibilityCriteria":343,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":344,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":346,"conditions":347,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":328,"lastUpdatePostDateStruct":350,"startDateStruct":351,"completionDateStruct":353,"leadSponsor":355,"locationsCount":357},"100473845","filter-lifespan-in-continuous-renal-replacement-therapy-100473845","NCT05450185","Filter Lifespan in Continuous Renal Replacement Therapy","The Effect of Filter Lifespan in Continuous Renal Replacement Therapy on the Rate of New Infections in Critically Ill Patients: a Prospective, Multicenter, Observational Trial","CRRTInfO","Inclusion Criteria:\n\n* Adult patients (age ≥18 years)\n* Critically ill patients with dialysis-dependent AKI\n* Continuous renal replacement therapy (CRRT)\n* Written informed consent\n\nExclusion Criteria:\n\n* Chronic kidney disease with estimated glomerular filtration rate (eGFR)\\\u003C30ml\u002Fmin\u002F1.73m2\n* Chronic dialysis dependency\n* Kidney transplant\n* (Glomerulo-)nephritis, interstitial nephritis, vasculitis\n* Patients on immunosuppression\n* Patients with chronic inflammatory diseases (e.g. arthritis, HIV, chronic hepatitis)\n* Persons with any kind of dependency on the investigator or employed by the sponsor or investigator",{"count":345,"type":22},600,"The only supportive therapy for patients with AKI is renal replacement therapy (RRT). In the ICU setting, continuous RRT (CRRT) is mostly favored. In a post-hoc analysis of the RICH trial (regional citrate versus systemic heparin anticoagulation for CRRT in critically ill patient with AKI), it was shown that the filter life span is associated with an increased rate of new infection and that the type of anticoagulants did not directly affect infection rate. The mechanisms of this infection rate is unknown.",[26,348,349],"Continuous Renal Replacement Therapy","Infections",{"date":330,"type":39},{"date":352,"type":39},"2023-03-02",{"date":354,"type":22},"2025-08",{"name":356,"class":46},"University Hospital Muenster",5,{"id":359,"slug":360,"hasResults":11,"nctId":361,"briefTitle":362,"officialTitle":362,"acronym":363,"eligibilityCriteria":364,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":365,"targetDuration":4,"studyType":109,"phases":367,"briefSummary":368,"conditions":369,"keywords":372,"overallStatus":175,"whyStopped":4,"lastUpdateSubmitDate":375,"lastUpdatePostDateStruct":376,"startDateStruct":378,"completionDateStruct":380,"leadSponsor":382,"locationsCount":4},"100550466","clinical-outcomes-of-mega-dosage-supplementations-of-cholecalciferol-in-critically-ill-patients-with-sepsis-100550466","NCT06447441","Clinical Outcomes Of Mega-dosage Supplementations Of Cholecalciferol In Critically Ill Patients With Sepsis","MDC-S","Inclusion Criteria:\n\n1. Medical subject ≥ 18 years old and diagnosed with sepsis\n2. Transferred to the intensive care unit within 24 hours after being diagnosed with sepsis\n3. Admitted to the ICU with 40 \\> APACHE II score ≥ 15.\n4. The intensivist anticipates that the subject will stay in the ICU ≥ 7 days.\n\nExclusion Criteria:\n\n1. Diseases that affect serum levels of 25(OH)D and calcium, including thyroidectomy, parathyroid disease, rickets, or severe cirrhosis \\[Child C\\]\n2. Received large doses of vitamin D3 in the past four weeks (\\> 2000 IU per day or ≥ 10,000 IU in a single dose)\n3. Admitted to the ICU with diagnosis of COVID-19\n4. AIDS subjects taking immunosuppressants\n5. Organ transplant\n6. Active cancer\n7. Tuberculosis, sarcoidosis, or kidney stones in the past one year\n8. Weight \\\u003C 45 kg or \\> 90 kg\n9. Had been admitted to ICU in the past three months\n10. Subject and family members who do not speak the native language\n11. Pregnant women",{"count":366,"type":22},240,[111],"Non-COVID-19 sepsis (Sepsis) has always been one of the common diseases in critically ill patients. The main treatment strategy is to kill pathogens and mitigate hyperinflammation. One study demonstrated that the supplementation with 576,000 IU cholecalciferol (vitamin D3) as a single dose in critically ill adults in the medical intensive care units (MICUs) can improve clinical outcomes, including acute physiology and chronic health evaluation II score (APACHE II), sequential organ failure assessment score (SOFA), and C-reactive protein (CRP).\n\nIt is a three-year, multi-center, prospective, parallel, double-blind, randomized controlled clinical trial for 240 eligible subjects, with administrations of vitamin D3 576,000 IU or placebo every 24 hours for 3 days (72 hours) within 96 hours after intensive care unit (ICU) admission.",[26,273,370,371],"Mortality Rate","Critical Care",[373,374,273],"Vitamin D","Cholecalciferol","2024-06-14",{"date":377,"type":39},"2024-06-17",{"date":379,"type":22},"2024-07-01",{"date":381,"type":22},"2029-12-31",{"name":383,"class":46},"Chimei Medical Center",{"id":385,"slug":386,"hasResults":11,"nctId":387,"briefTitle":388,"officialTitle":389,"acronym":390,"eligibilityCriteria":391,"healthyVolunteers":392,"sex":17,"minAge":18,"maxAge":393,"enrollmentInfo":394,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":396,"conditions":397,"keywords":405,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":413,"lastUpdatePostDateStruct":414,"startDateStruct":416,"completionDateStruct":418,"leadSponsor":420,"locationsCount":47},"100289166","monocyte-profiles-in-critically-ill-patients-with-pseudomonas-aeruginosa-sepsis-100289166","NCT03044223","Monocyte Profiles in Critically Ill Patients With Pseudomonas Aeruginosa Sepsis","Phenotypical Und Functional Characterization of Macrophages in Critically Ill Patients With Pseudomonas Aeruginosa Induced Sepsis","MIPSA","Inclusion Criteria:\n\n* age \\> 18 years\n* critically ill patients with sepsis\n* microbiologically proven infection with Pseudomonas aeruginosa\n\nExclusion Criteria:\n\n* life expectancy \\\u003C 24 hours\n* participation in other studies",true,"90 Years",{"count":395,"type":22},100,"The present study focuses on patients with Pseudomonas aeruginosa (PSA) sepsis. The aim of the present study is to find out whether the M1 (pro-inflammatory) or M2 (anti-inflammatory) phenotype predominates in blood monocytes in critically ill patients with PSA-sepsis, and whether the severity of sepsis and outcome is associated with distinct monocyte phenotype and function.",[398,399,400,401,402,403,273,404,26],"Pseudomonas Infections","Pseudomonas Septicemia","Pseudomonas; Pneumonia","Pseudomonal Bacteraemia","Pseudomonas Urinary Tract Infection","Pseudomonas Gastrointestinal Tract Infection","Sepsis, Severe",[406,407,408,409,410,411,412],"pseudomonas aeruginosa","critically ill patient","sepsis","monocyte","macrophage","cytokine","severity of disease","2024-01-16",{"date":415,"type":39},"2024-01-17",{"date":417,"type":4},"2014-08",{"date":419,"type":22},"2026-12",{"name":421,"class":46},"University of Ulm",{"id":423,"slug":424,"hasResults":11,"nctId":425,"briefTitle":426,"officialTitle":427,"acronym":4,"eligibilityCriteria":428,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":429,"targetDuration":431,"studyType":23,"phases":4,"briefSummary":432,"conditions":433,"keywords":437,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":441,"lastUpdatePostDateStruct":442,"startDateStruct":444,"completionDateStruct":446,"leadSponsor":448,"locationsCount":450},"100346632","the-excel-registry-of-patients-requiring-ecmo-100346632","NCT03793257","The EXCEL Registry of Patients Requiring ECMO","The EXCEL Registry: A Comprehensive Binational Registry on the Treatment and Outcomes of Patients Requiring ECMO","Inclusion Criteria:\n\n* Patients admitted to adult hospitals and receive ECMO in Australia and New Zealand\n\nNil Exclusion Criteria",{"count":430,"type":22},3000,"12 Months","ECMO is associated with significant costs, risks and requires specialist training and expertise. EXCEL is a novel, high-quality, detailed prospective registry of patients requiring ECMO in Australia and New Zealand. The registry provides information on patient selection, complications, costs and patient reported outcome measures. EXCEL uses the Theoretical Domains Framework to identify evidence-practice gaps and explore barriers and enablers to tailor implementation of evidence",[26,434,435,436],"Acute Respiratory Failure","Acute Heart Failure","Cardiac Arrest",[438,371,439,440],"Intensive Care","Extracorporeal Membrane Oxygenation","Extracorporeal Life Support","2023-09-13",{"date":443,"type":39},"2023-09-15",{"date":445,"type":39},"2019-02-01",{"date":447,"type":22},"2027-12-31",{"name":449,"class":46},"Australian and New Zealand Intensive Care Research Centre",29,{"id":452,"slug":453,"hasResults":11,"nctId":454,"briefTitle":455,"officialTitle":456,"acronym":457,"eligibilityCriteria":458,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":459,"targetDuration":4,"studyType":109,"phases":461,"briefSummary":462,"conditions":463,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":466,"lastUpdatePostDateStruct":467,"startDateStruct":469,"completionDateStruct":471,"leadSponsor":473,"locationsCount":47},"100447891","the-effects-of-pancreatic-enzyme-supplementation-in-critically-ill-patients-on-enteral-feeding-100447891","NCT05112328","The Effects of Pancreatic Enzyme Supplementation in Critically Ill Patients on Enteral Feeding","The Effects of Pancreatic Enzyme Supplementation in Critically Ill Patients on Enteral Feeding: Prospective Randomized Controlled Trial","PREZENT","Inclusion Criteria:\n\n* Adults 19 years and older\n* Hospitalized in the surgical\u002Fmedical intensive care unit of the Seoul National University Hospital\n* Enteral nutrition\n* Patients who consented to this study\n* Patients with risk factors for pancreatic exocrine dysfunction\n\n  * Shock (Norepinephrine)\n  * Sepsis (3 rd definition of sepsis)\n  * Diabetes\n  * Cardiac arrest\n  * hyperlactatemia serum lactate \\> 2 mmol\u002FL)\n  * Mechanical ventilation\n  * Continuous renal replacement therapy\n\nExclusion Criteria:\n\n* chronic pancreatitis\n* unresectable pancreatic cancer\n* History of pancreatectomy\n* Underlying diseases in which the effect of Exocrine pancreatic enzyme administration is difficult to show\n\n  * Inflammatory bowel disease\n  * Short bowel syndrome",{"count":460,"type":22},170,[111],"Determine the effect of high-dose pancreatic enzyme supplementation on nutritional indicators and clinical course in critically ill patients undergoing enteral nutrition.",[26,464,465],"Enteral Feeding","Exocrine Pancreatic Insufficiency","2021-11-04",{"date":468,"type":39},"2021-11-08",{"date":470,"type":39},"2021-07-07",{"date":472,"type":22},"2026-07-31",{"name":474,"class":46},"Seoul National University Hospital"]